Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 4/20 | 0.78 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.63 |
| ▸ | ACHE | P22303 | 5/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5531230 | 0.91 | EDNRA (0.66) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL5530761 | 0.91 | EDNRA (0.80) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL5534079 | 0.91 | EDNRA (0.80) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL5523049 | 0.90 | EDNRA (0.64) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL5532320 | 0.90 | AGTR1 (0.66) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL5531270 | 0.88 | EDNRA (0.69) | EDNRAAGTR1ACHEAGTR2 | |
| SCHEMBL5537259 | 0.88 | EDNRA (0.82) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL4773774 | 0.88 | EDNRA (1.00) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL4774226 | 0.86 | EDNRA (0.84) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL5527508 | 0.85 | EDNRA (0.59) | EDNRAAGTR1ACHEAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | claimed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | claimed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | claimed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | claimed |
| EP-1237888-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2002-09-11 | — | — | EP | claimed |
| WO-2001044239-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR1 4/4885ACHE 1584/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR1 4/4885ACHE 1584/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR1 4/4885ACHE 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.